Carl Dambkowski, MD
Head of R&D, Paragon LabsDr Dambkowski is the Head of R&D at Paragon Labs.
Prior to joining Paragon, he served as Chief Medical Officer of Apogee Therapeutics through its 2026 acquisition by AbbVie. Previously, he served as a strategic and clinical leader for a variety of companies, including as part of the core teams at QED Therapeutics and Origin Biosciences as they brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval. Additionally, he has served as Associate at McKinsey & Company and co-founded the private medical device company Novonate.
Dr Dambkowski holds a BS and MD from Stanford University in addition to an MA from Columbia University.